Publishing their findings in PLOS Medicine, researchers studied 1,147 HIV-negative participants drawn from the three Ugandan sites of the Partners PrEP Study, which gives participants either Viread or Truvada in order to prevent the acquisition of HIV.
http://www.poz.com/articles/PrEP_Adherence_761_24515.shtml
http://www.poz.com/articles/PrEP_Adherence_761_24515.shtml
No comments:
Post a Comment